Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics announced that Waylivra™ (volanesorsen) has received Category 1 classification from Brazil's CMED, making it the only treatment for familial chylomicronemia syndrome (FCS) available in the country. This classification recognizes its greater efficacy over current treatments and allows for international pricing. Furthermore, PTC submitted an application to ANVISA for Waylivra’s approval for familial partial lipodystrophy (FPL), potentially marking the first approved treatment for FPL globally. A decision from ANVISA is expected in the latter half of 2022.
PTC Therapeutics will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10, 2022, at 7:30 a.m. EST. The live webcast can be accessed on PTC's Investor Events and Presentations page and will be archived for 30 days. PTC Therapeutics focuses on developing and commercializing medicines for rare disorders, with a commitment to providing access to innovative treatments for patients in need.
PTC Therapeutics (PTCT) announced the publication in Nature Communications detailing a novel splicing mechanism from its Huntington Disease (HD) program. This mechanism selectively lowers huntingtin protein levels via innovative splicing modifiers. CEO Stuart W. Peltz highlighted the breakthrough's potential to regulate gene expression, benefiting various diseases. HD affects around 45,000 individuals in the U.S., with no existing treatments targeting its underlying cause. PTC aims to leverage its splicing platform for new therapies, enhancing its pipeline of medicines for rare disorders.
PTC Therapeutics announced that its oral therapy Evrysdi® (risdiplam) has received prestigious awards for its innovation and life-saving effects. Recognized as the 2022 Drug Discovery of the Year by the British Pharmacological Society and the 2021 Drug Discovery Prize by the Society for Medicines Research, Evrysdi aims to treat spinal muscular atrophy (SMA) by enhancing SMN protein levels. The drug is commercialized by Roche and Genentech in the U.S., showcasing PTC's commitment to addressing unmet medical needs through innovative therapies.
PTC Therapeutics, Inc. (PTCT) has announced the approval of stock options for 49 new employees, totaling 83,750 shares, and 21,550 restricted stock units (RSUs). The awards, effective as of November 29, 2021, serve as an employment inducement under NASDAQ Listing Rule 5635(c)(4). Each stock option has an exercise price of $36.89 and a 10-year term, with vesting occurring over four years. The RSUs will also vest over four years. These grants reflect PTC's commitment to attract talent in the biopharmaceutical sector.
PTC Therapeutics (NASDAQ: PTCT) will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET. The presentation will be available via a live webcast on PTC's Investor website and archived for 30 days. PTC focuses on developing clinically differentiated medicines for rare disorders, leveraging its scientific expertise and global infrastructure to address unmet medical needs. For more details, visit www.ptcbio.com.
PTC Therapeutics (NASDAQ: PTCT) reported a 39% growth in its Duchenne muscular dystrophy (DMD) franchise, with third-quarter net product revenue reaching $114 million. Total revenues increased to $138.7 million, compared to $118.4 million in Q3 2020. The company anticipates full-year DMD franchise revenues between $400 and $420 million, adjusting previous guidance. However, net losses rose to $133.6 million from $69.7 million year-on-year, and cash reserves decreased to $867.9 million. PTC continues advancements across its clinical pipeline with several ongoing trials.
PTC Therapeutics will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Nov. 9, 2021, at 8:00 a.m. ET. The presentation will be accessible via a live webcast on the company's investor site and archived for 30 days post-event. PTC focuses on developing innovative treatments for rare disorders, emphasizing a strong scientific foundation and global commercial capabilities to meet unmet patient needs.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that Brazil's ANVISA has approved the expansion of Translarna™ (ataluren) to include children aged 2 to 5 with nonsense mutation Duchenne muscular dystrophy (Duchenne). This broadens the prior indication of 5 years and older, allowing earlier treatment that may preserve muscle function and slow disease progression. Translarna is the sole treatment targeting the underlying cause of Duchenne due to a nonsense mutation and is licensed in the EEA for ambulatory patients aged 2 and older.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on Oct. 28, 2021, at 4:30 p.m. ET to report its third quarter financial results and provide a business update. Investors can join the call by dialing (877) 303-9216 in the U.S. or (973) 935-8152 internationally, using passcode 8574103. A live webcast will be available on the company's investor website, with a replay accessible two hours post-call and archived for 30 days. PTC focuses on developing innovative treatments for rare disorders, backed by a robust product pipeline.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
